Trial Profile
A 21-Week, Open-label, Randomized, Controlled, Parallel-group, Multi-center Study Evaluating the Efficacy and Safety of HOE901-U300 Administered According to a Device-Supported Treat-to-target Regimen Versus Routine Titration in Patients with Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms AUTOMATIX
- Sponsors Sanofi
- 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 26 Jun 2018 Results assessing self-titration vs. physician-led titration from TAKE CONTROL, AUTOMATIX and INNOVATE trials presented at the 78th Annual Scientific Sessions of the American Diabetes Association
- 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.